Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $AVXL
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/6/2022 | $16.00 → $11.00 | Overweight → Neutral | Cantor Fitzgerald |
6/23/2022 | $40.00 | Buy | Berenberg |
2/2/2022 | $39.00 → $42.00 | Buy | HC Wainwright & Co. |
9/23/2021 | $35.00 | Buy | BTIG Research |
6/28/2021 | $25.00 → $39.00 | Buy | HC Wainwright & Co. |
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7 – 10, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:45 PM (ET) on Monday, April 7th, 2025. A live audio webcast will be accessible th
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c
Anavex downgraded by Cantor Fitzgerald with a new price target
Cantor Fitzgerald downgraded Anavex from Overweight to Neutral and set a new price target of $11.00 from $16.00 previously
Berenberg initiated coverage on Anavex with a new price target
Berenberg initiated coverage of Anavex with a rating of Buy and set a new price target of $40.00
HC Wainwright & Co. reiterated coverage on Anavex Life Sciences with a new price target
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $42.00 from $39.00 previously
Director Donhauser Peter D.O. bought $10,319 worth of shares (2,835 units at $3.64), increasing direct ownership by 131% to 5,000 units (SEC Form 4)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
Thomas Steffen bought $22,600 worth of shares (5,000 units at $4.52) (SEC Form 4)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
SEC Form 4 filed by Director Donhauser Peter D.O.
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
SEC Form 4 filed by Director Ma Jiong
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
SEC Form 4 filed by Director Skarpelos Athanasios
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
SEC Form 10-Q filed by Anavex Life Sciences Corp.
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
SEC Form 10-K filed by Anavex Life Sciences Corp.
10-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
SEC Form 10-Q filed by Anavex Life Sciences Corp.
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
Anavex Life Sciences Announces Expansion of Leadership Team
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n
Anavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13, 2024 deadline
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Anavex is engaged in the research, production, and marketing of p
Anavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 18, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing c
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first fiscal quarter on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Follow
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains de
SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)